Global Human Insulin Market 2011-2015

TechNavio's analysts forecast the Global Human Insulin market to grow at a CAGR of -4.02 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the number of patients suffering from diabetes and diabetes-related diseases worldwide. The Global Human Insulin market has also been witnessing the trend of rapid growth in the APAC region. However, the increased risk of cancer with human insulin use could pose a challenge to the growth of this market.

TechNavio's report, the Global Human Insulin Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Bayer Healthcare AG, Eli Lilly & Co., Novo Nordisk A/S, and Sanofi S.A.

Other vendors mentioned in the report: Abbott Laboratories Inc., Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., and Pfizer Inc.

Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

01. Executive Summary
02. Introduction
03. Market Coverage
Overview
Key Offerings
04. Market Landscape
04.1 Global Insulin Market
04.2 Global Human Insulin Market
Market Size
Market Forecast
Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
USA
China
Germany
07. Rate of Incidence and Prevalence
Diabetes
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Novo Nordisk A/S
Business Overview
SWOT Analysis
15.2 Eli Lilly and Co.
Business Overview
SWOT Analysis
15.3 Bayer Healthcare AG
Business Overview
SWOT Analysis
15.4 Sanofi
Business Overview
SWOT Analysis
16. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Insulin Market 2011-2015 (US$ billion)
Exhibit 2: Global Insulin Market by Product Segmentation
Exhibit 3: Global Insulin Market by Category Segmentation 2011
Exhibit 4: Global Insulin Market 2011-2015 by Revenue Segmentation (US$ billion)
Exhibit 5: Global Insulin Market 2011-2015 by Segmentation (percentage)
Exhibit 6: Global Human Insulin Market 2011-2015 (US$ billion)
Exhibit 7: Global Human Insulin Market by Geographical Segmentation 2011
Exhibit 8: Estimated Preventable Cases of Diabetes per Year in the US (percentage)
Exhibit 9: Global Human Insulin Market by Vendor Segmentation 2011